ProMIS Neurosciences to Present at 2022 Alzheimer’s Association International Conference
July 27 2022 - 7:00AM
ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology
company focused on the discovery and development of antibody
therapeutics targeting misfolded proteins such as toxic oligomers,
implicated in the development of neurodegenerative diseases, today
announced it will give a poster presentation at the annual
Alzheimer’s Association International Conference (AAIC®) to be held
July 31-August 4, 2022 at the San Diego Convention Center, San
Diego California and online.
Dr. Johanne Kaplan, ProMIS Chief Development Officer, will
present the poster entitled: “Distinguishing between
amyloid-beta-directed antibodies: ability of PMN310 to target toxic
oligomers despite competing species.” The poster describes the
design and results of a study wherein ProMIS’ lead therapeutic
candidate PMN310 was compared to other amyloid-beta-directed
antibodies for selectivity and ability to maintain interaction with
toxic oligomers in the presence of competing monomers.
Dr. Kaplan will deliver her poster presentation (P1-090) on July
31 from 12:30 - 2:15 PM local time in person at
the San Diego Convention Center Exhibit Hall and online. Please
consult the AAIC® website (https://alz.org/aaic/overview.asp) for
any further updates. The poster presentation will be available on
the ProMIS website (www.promisneurosciences.com) after the AAIC®
closes on Aug 4, 2022.
AAIC® is the largest, most influential international meeting
focused on advancing dementia science. The annual conference
convenes the world’s leading basic science and clinical
researchers, next-generation investigators, clinicians and the care
community to share research discoveries supporting new methods of
prevention, treatment and diagnosis of Alzheimer’s disease.
About PMN310ProMIS
Neurosciences’ lead therapeutic candidate, PMN310, is a monoclonal
antibody for Alzheimer’s disease created with a novel, proprietary
method for generating and developing antibodies that can uniquely
and precisely target toxic forms of otherwise normal proteins.
PMN310 selectively targets the toxic oligomeric species of
amyloid-beta (Aß), a root cause of Alzheimer’s disease. Preclinical
studies have shown that PMN310 demonstrates a high degree of
binding to toxic oligomers as opposed to non-toxic forms of Aß,
possessing greater selectivity versus other Aß-directed
antibodies.
About ProMIS Neurosciences ProMIS Neurosciences
Inc. is a development stage biotechnology company focused on
generating and developing antibody therapeutics selectively
targeting toxic oligomers implicated in the development and
progression of neurodegenerative diseases, in particular
Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and
Parkinson’s disease (PD). The Company’s proprietary target
discovery engine is based on the use of two complementary
techniques. The Company applies its thermodynamic, computational
discovery platforms - ProMIS™ and Collective Coordinates - to
predict novel targets known as Disease Specific Epitopes on the
molecular surface of misfolded proteins. Using this unique
approach, the Company is developing novel antibody therapeutics for
AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with
offices in Cambridge, Massachusetts. ProMIS is listed on Nasdaq and
the Toronto Stock Exchange under the symbol PMN.
To learn more, visit us at www.promisneurosciences.com, follow
us on Twitter and LinkedIn
For Investor Relations please contact:Alpine Equity
AdvisorsNicholas Rigopulos, Presidentnick@alpineequityadv.comTel.
617 901-0785
The TSX has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release. This information release
contains certain forward-looking information. Such information
involves known and unknown risks, uncertainties and other factors
that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and
therefore these statements should not be read as guarantees of
future performance or results. All forward-looking statements are
based on the Company's current beliefs as well as assumptions made
by and information currently available to it as well as other
factors. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks
and uncertainties identified by the Company in its public
securities filings, actual events may differ materially from
current expectations. The Company disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
###
ProMIS Neurosciences (TSX:PMN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ProMIS Neurosciences (TSX:PMN)
Historical Stock Chart
From Jul 2023 to Jul 2024